Knobbe Martens

Before Stark, Lourie, and Bryson. Appeal from the United States District Court for the District of Connecticut. Summary: A narrowly defined patent...

(October 17, 2024) - Knobbe Martens attorneys Douglas Wentzel and Joshua Martineau describe the options patent holders have when the validity of

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The...

On October 2, 2024, the U.S. Department of Agriculture (USDA), U.S. Environmental Protection Agency (EPA), and U.S. Food and Drug Administration (FDA)...

Failure to Obtain Advice of a Third Party Is Not Evidence of Willfulness

As the FTC continues to crack down on pharmaceutical manufacturers’ allegedly improper listing of patents in the FDA Orange Book, counsel...

In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson [1], the plaintiffs successfully overcame a motion to dismiss. At the heart of the case is J&J’s legal strategy against biosimilar competitors, including Amgen, and the role of settlement agreements in controlling market entry dates for biosimilars. As this case demonstrates, actions taken in patent prosecution, litigation, and inter partes review (IPR) proceedings can have significant downstream consequences, including antitrust scrutiny from insurers and healthcare providers.

UTTO INC. v. METROTECH CORP. Before Prost, Taranto, and Hughes. Appeal from the United States District Court for the Northern District of California....

Before Lourie, Prost, and Reyna. Appeal from the Eastern District of North Carolina.

Market reports indicate the global medical device industry for Q3 2024 saw an increase in merger and acquisition (M&A) activity in terms of value year-over-year. Although deal value decreased compared to Q2 2024, deal volume increased compared to Q2 2024 and year-over-year. One report